Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 4, 2013, Pages 436-441

  Messeguer, F ^a   Agusti Mejias A ^b   Traves, V ^a   Requena, C ^b   Alegre, V ^b   Guillen C ^a   Oliver, V ^b   Nagore, E ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CUTANEOUS MELANOMA; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; MITOSIS RATE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SKIN METASTASIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MITOSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 84875363693     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04454.x     Document Type: Article

References (26)

1. de Vries E, Bray FI, Coebergh JW, et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119-126.
2. Reintgen DS, Vollmer R, Tso CY, et al. Prognosis for recurrent stage I malignant melanoma. Arch Surg 1987; 122: 1338-1342.
3. Leiter U, Meier F, Schittek B, et al. The natural course of cutaneous melanoma. J Surg Oncol 2004; 86: 172-178.
4. Reintgen DS, Cox C, Slingluff CL Jr, et al. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992; 28: 45-49.
5. Markowitz JS, Cosimi LA, Carey RW, et al. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 1991; 126: 703-707. discussion 7-8.
6. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
7. Tejera-Vaquerizo A, Barrera-Vigo MV, Fernandez-Canedo I, et al. Longitudinal study of different metastatic patterns in the progression of cutaneous melanoma. Actas Dermosifiliogr 2007; 98: 531-538.
8. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147: 62-70.
9. Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 2008; 15: 1476-1484.
10. Soong SJ, Harrison RA, McCarthy WH, et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998; 67: 228-233.
11. Savoia P, Fava P, Nardo T, et al. Skin metastases of malignant melanoma: a clinical and prognostic survey. Melanoma Res 2009; 19: 321-326.
12. Buzzell RA, Zitelli JA,. Favorable prognostic factors in recurrent and metastatic melanoma. J Am Acad Dermatol 1996; 34: 798-803.
13. Dong XD, Tyler D, Johnson JL, et al. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer 2000; 88: 1063-1071.
14. Yu LL, Heenan PJ,. The morphological features of locally recurrent melanoma and cutaneous metastases of melanoma. Hum Pathol 1999; 30: 551-555.
15. Heenan PJ, Ghaznawie M,. The pathogenesis of local recurrence of melanoma at the primary excision site. Br J Plast Surg 1999; 52: 209-213.
16. Roach BA, Burton AL, Mays MP, et al. Does mitotic rate predict sentinel lymph node metastasis or survival in patients with intermediate and thick melanoma? Am J Surg 2010; 200: 759-763. discussion 63-64.
17. Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011; 29: 2199-2205.
18. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
19. Nagore E, Oliver V, Botella-Estrada R, et al. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res 2005; 15: 169-177.
20. Kretschmer L, Beckmann I, Thoms KM, et al. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma. Ann Surg Oncol 2006; 13: 1105-1112.
21. Borgstein PJ, Meijer S, van Diest PJ,. Are locoregional cutaneous metastases in melanoma predictable? Ann Surg Oncol 1999; 6: 315-321.
22. Nagore E, Botella-Estrada R, Sanmartin O, et al. Imiquimod for the treatment of skin metastases of melanoma. Actas Dermosifiliogr 2005; 96: 549-550.
23. Turza K, Dengel LT, Harris RC, et al. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. J Cutan Pathol 2010; 37: 94-98.
24. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488-1498.
25. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 2004; 11: 426-433.
26. Nagore E, Oliver V, Botella-Estrada R, et al. Clinicopathological analysis of 1571 cutaneous malignant melanomas in Valencia, Spain: factors related to tumour thickness. Acta Dermatovenereol 2006; 86: 50-56.